ENXTPA:DBVBiotechs
DBV Technologies (ENXTPA:DBV) Is Up 11.8% After Phase 3 Peanut Patch Success Has The Bull Case Changed?
DBV Technologies recently reported that its Phase 3 VITESSE trial of the VIASKIN Peanut patch for peanut‑allergic children aged 4–7 met its primary endpoint with statistically significant efficacy and a favorable safety profile, and the company now plans to submit a Biologics License Application to the US FDA in the first half of 2026.
An important angle for investors is that this late-stage success follows earlier regulatory setbacks, suggesting the redesigned patch and trial design may...